Literature DB >> 10754085

Cardiac manifestations in patients with HLA B27-associated juvenile arthritis.

H Huppertz1, I Voigt, J Müller-Scholden, K Sandhage.   

Abstract

Cardiac involvement is common in adult patients with the presence of HLA B27 with or without the HLA B27-associated spondyloarthropathy ankylosing spondylitis. Most patients with juvenile spondyloarthropathy, which begins at age 16 or younger, do not have spinal involvement and there are only few reports of cardiac involvement. This study sought to assess the prevalence of carditis in patients with HLA B27-associated juvenile arthritis (B27-JA). In a controlled study, 40 patients with B27-JA, among them only 1 with ankylosing spondylitis, were examined by electrocardiogram and echocardiography with pulsed and color-flow Doppler at rest and at the termination of a bicycle exercise and compared to an age- and sex-matched control group negative for HLA B27. Four patients with B27-JA, and none in the control group, had inflammatory aortic regurgitation. Late diastolic flow velocity was significantly increased in patients with B27-JA at the termination of exercise. HLA B27 is a risk factor for endo-/myocardial damage in patients with B27-JA, even in the presence of only short and mild articular disease. Patients with B27-JA should be screened for the presence of aortic regurgitation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10754085     DOI: 10.1007/s002469910023

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  12 in total

Review 1.  Juvenile spondyloarthritis.

Authors:  Sabrina Gmuca; Pamela F Weiss
Journal:  Curr Opin Rheumatol       Date:  2015-07       Impact factor: 5.006

2.  QT dispersion and cardiac involvement in patients with juvenile idiopathic arthritis.

Authors:  Bülent Koca; Ozgür Kasapçopur; Süleyman Bakari; Emre Celik; Ozden Calay
Journal:  Rheumatol Int       Date:  2011-09-27       Impact factor: 2.631

Review 3.  Cardiac involvement in juvenile idiopathic arthritis.

Authors:  Bulent Koca; Sezgin Sahin; Amra Adrovic; Kenan Barut; Ozgur Kasapcopur
Journal:  Rheumatol Int       Date:  2016-07-14       Impact factor: 2.631

4.  Use of tissue Doppler and its comparison with other pulse Doppler echocardiography in the evaluation of diastolic functions in patients with active juvenile idiopathic arthritis.

Authors:  Bülent Koca; Tevfik Demir; Özgür Kasapçopur
Journal:  Clin Rheumatol       Date:  2014-08-23       Impact factor: 2.980

5.  The forgotten chamber: right-ventricular functions in juvenile idiopathic arthritis.

Authors:  Mehtap Haktanir Abul; Muferet Erguven; Beste Ozben; Yusuf Izzet Ayhan
Journal:  Pediatr Cardiol       Date:  2012-02-17       Impact factor: 1.655

6.  Aortic valve insufficiency in patients with chronic rheumatic diseases.

Authors:  Paavo Uusimaa; Maija-Liisa Krogerus; Juhani Airaksinen; Markku Linnaluoto; Osmo Tervonen; Markku Hakala
Journal:  Clin Rheumatol       Date:  2005-10-11       Impact factor: 2.980

Review 7.  [Echocardiographic functional analysis of patients with rheumatoid arthritis and collagen diseases].

Authors:  A Hagendorff; D Pfeiffer
Journal:  Z Rheumatol       Date:  2005-05       Impact factor: 1.372

8.  Assessment of cardiac and pulmonary function in children with juvenile idiopathic arthritis.

Authors:  Eman A M Alkady; Hatem A R Helmy; Aliaë A R Mohamed-Hussein
Journal:  Rheumatol Int       Date:  2010-07-24       Impact factor: 2.631

9.  The Development of Extra-Articular Manifestations in Children With Enthesitis-Related Arthritis: Natural Course or Different Disease Entity?

Authors:  Ilaria Pagnini; Mariangela Scavone; Ilaria Maccora; Maria Vincenza Mastrolia; Edoardo Marrani; Federico Bertini; Lovro Lamot; Gabriele Simonini
Journal:  Front Med (Lausanne)       Date:  2021-05-13

10.  P wave dispersion in juvenile idiopathic arthritis patients with diastolic dysfunction.

Authors:  Bülent Koca; Süleyman Bakari; Ozgür Kasapçopur; Emre Celik; Funda Oztunç; Ayşe Güler Eroğlu; Levent Saltik
Journal:  Iran J Pediatr       Date:  2012-12       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.